NIH funds expanded access projects for ALS
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi! Today, we discuss why an advisory committee was…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hi! Today, we discuss why an advisory committee was not thrilled with Amgen’s data for Lumakras, and Neurocrine Biosciences has a potential blockbuster up its sleeve. Oh, and we’ll be off for Indigenous Peoples’ Day next week and will be back in your inbox Tuesday!
What's Your Reaction?
